MNI BRIEF: US May Existing Home Sales Pace Falls 0.7% To 4.11M

MNI INTERVIEW2: Uninsured Bank Deposits Still Vulnerable-Bair

CANADA APR RETAILS +0.7%, MATCHING FORECAST, PRIOR -0.3%

MNI BRIEF: China Hopes EU To Ease Frictions Via Negotiations

MNI: PBOC Net Injects CNY8 Bln Via OMO Fri; Rates Unchanged

MNI: PBOC Sets Yuan Parity Higher At 7.1196 Fri; -1.41% Y/Y

MNI: BAKER HUGHES US RIG COUNT 588; OIL RIGS 485; GAS RIGS 98

EZ/UK Bond Supply Calendar: EU Auction, BoE APF Monday

EZ/UK T-Bill Calendar: Germany, France Auction on Monday

RPT-MNI: Canada Sticks To Fiscal Anchors, Spends Chunk Of Windfall

MNI BRIEF: Poilievre Calls QE 'Scam' And Would Limit BOC Remit

MNI: Growth Drag From Net Zero Carbon Goal Can Be Offset-OECD

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

Satorius +10%, Longer Spreads -13bp On 24/28 Outlook

HEALTHCARE


  • FY23 results saw rev of EU3.4 bn, adj- EBITDA of EU962 and adj-EBITDA Margin of 28.3% all in line with BBG consensus.
  • EBITDA leverage rose to 5x from 1.7x at FY22 though this was driven by the acquisition of Polyplus and is seen reducing to 4x in 2024. Net OCF rose to €836mn from €734mn in FY22 driven by working capital optimisation
  • 2024 outlook includes “mid to high single-digit” revenue growth (1.5% of which non-organic), adj-EBITDA margin above 30% and capital expenditure as a percentage of revenue around 13% from 16.5% this year.
  • 2028 outlook sees average growth of ”lower double-digit percentage” (with acquisitions contributing about a fifth) and adj-EBITDA margins of ~34%.
  • Equity analysts at Jefferies and Morgan Stanley found the book-to-bill ratio above 1x and FY24 guidance encouraging, signalling a turnaround in the bioprocess solutions business.
Credit BulletsBulletHomepagemarkets-real-timeCredit
Credit BulletsBulletHomepagemarkets-real-timeCredit

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.